Abstract:Background Cilostazol combined with P2Y(12) receptor inhibitor has been used as a substitute regimen for aspirin-intolerant patients undergoing percutaneous coronary stent implantation on a small scale. Its exact impact on platelet functions and clinical benefits of aspirin-intolerant patients is unknown. Hypothesis Cilostazol combined with P2Y(12) receptor inhibitors could be used as a substitute antiplatelet regimen for aspirin-intolerant patients undergoing percutaneous coronary stent implantation. Methods In this multicenter prospective cohort trial, patients undergoing elective percutaneous coronary stent implantation were assigned to the cilostazol group (cilostazol plus P2Y(12) receptor inhibitors), based on aspirin intolerance criteria, or the aspirin group (aspirin plus P2Y(12) receptor inhibitors). Platelet PAC-1, CD62p, and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P) were detected by flow cytometry. The primary endpoints were major adverse cardiovascular and cerebrovascular events (MACCE) including all-cause death, acute myocardial infarction, emerging arrhythmia, nonfatal stroke, and heart failure. The secondary endpoints were the Bleeding Academic Research Consortium (BARC) bleeding events. Results One hundred and fifty-four aspirin-intolerant percutaneous coronary stent implantation patients and 154 matched aspirin-tolerant patients from a total of 2059 percutaneous coronary stent implantation patients were enrolled. The relative activation level of PAC-1, CD62p, and platelet reaction index reflected by the VASP-P test were similar in the two groups (p > .05). After 12 months of follow-up, the incidence of all-cause death was 1.9% in the cilostazol group and 1.3% in the aspirin group (risk ratio [RR], 1.500; 95% confidence interval [CI], 0.254-8.852; p = 1.000); the incidence of acute myocardial infarction was 0.6% in the cilostazol group and 1.3% in the aspirin group (RR, 0.500; 95% CI, 0.046-5.457; p = 1.000). No significant difference was seen in other MACCE events, or in any types of BARC bleeding events. Conclusions Cilostazol combined with P2Y(12) inhibitors was not inferior to aspirin-based standard therapy and could be used as a reasonable substitute antiplatelet regimen for aspirin-intolerant patients undergoing percutaneous coronary stent implantation, but again with limitations, which required a larger sample and longer follow-up to confirm its efficacy.

Cilostazol Increases Adenosine Plasma Concentration in Patients with Acute Coronary Syndrome

Effects of Diltiazem on Platelet Activation and Cytosolic Calcium During Percutaneous Transluminal Coronary Angioplasty.

Ticagrelor Enhances Adenosine-Mediated Antiplatelet Effect In Acute Coronary Syndrome Patients-A Prospective Cohort Study

Effects of Cilostazol on Thrombospondin-1 (TSP-1) Expression Changes in the Myocardium of Diabetic Rats.

Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention.

Cilostazol combined with P2Y<sub>12</sub> receptor inhibitors: A substitute antiplatelet regimen for aspirin-intolerant patients undergoing percutaneous coronary stent implantation

Phosphodiesterase inhibitor modulation of brain microvascular endothelial cell barrier properties.

Cilostazol in Addition to Aspirin and Clopidogrel Improves Long-Term Outcomes after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndromes: A Randomized, Controlled Study

A Randomized Controlled Trial Evaluating Outcome Impact of Cilostazol in Patients with Coronary Artery Disease or at a High Risk of Cardiovascular Disease

Cilostazol Enhances Mobilization of Circulating Endothelial Progenitor Cells and Improves Endothelium-Dependent Function in Patients at High Risk of Cardiovascular Disease

Differential inhibition of platelet function by cilostazol in combination with clopidogrel

A Review with Meta-Analysis

[Effects of Cilostazol on Long-Term Clinical Outcomes after Coronary Stenting].

Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique

Cilostazol for Chinese Patients with Aspirin Intolerance after Coronary Drug-Eluting Stent Implantation

Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels

RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome.

The Efficacy and Safety of Cilostazol As an Alternative to Aspirin in Chinese Patients with Aspirin Intolerance after Coronary Stent Implantation: a Combined Clinical Study and Computational System Pharmacology Analysis

Cilostazol Regulates the Expressions of Endothelin-1 and Endothelial Nitric Oxide Synthase Via Activation of the P38 MAPK Signaling Pathway in HUVECs.

Cilostazol May Prevent Cerebral Vasospasm Following Subarachnoid Hemorrhage

Comparison of Cilostazol Versus Clopidogrel in Addition to Aspirin in Patients with Ischemic Stroke Who Underwent Intracranial or Extracranial Artery Stent Implantation